IO Biotech Inc. (IOBT)
NASDAQ: IOBT
· Real-Time Price · USD
1.78
0.03 (1.71%)
At close: Sep 04, 2025, 3:59 PM
1.79
0.56%
Pre-market: Sep 05, 2025, 09:17 AM EDT
1.71% (1D)
| Bid | 1.75 |
| Market Cap | 117.27M |
| Revenue (ttm) | 850K |
| Net Income (ttm) | -103.99M |
| EPS (ttm) | -1.58 |
| PE Ratio (ttm) | -1.13 |
| Forward PE | -1.79 |
| Analyst | Buy |
| Ask | 1.81 |
| Volume | 906,440 |
| Avg. Volume (20D) | 3,094,795 |
| Open | 1.77 |
| Previous Close | 1.75 |
| Day's Range | 1.73 - 1.84 |
| 52-Week Range | 0.66 - 2.79 |
| Beta | 0.41 |
About IOBT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IOBT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IOBT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+68.75%
IO Biotech shares are trading higher following the...
Unlock content with
Pro Subscription
3 weeks ago
-41.99%
Shares are trading lower after the company said its Phase 3 trial of Cylembio plus Keytruda in advanced melanoma narrowly missed the primary endpoint.
3 weeks ago · seekingalpha.com
IO Biotech: A Buying Opportunity Following Phase 3 Readout In MelanomaIO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients, despite narrowly missing statistical significance. I believe the FDA should acce...
